Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Aligos Therapeutics. The associated price target remains the same with $50.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Aligos Therapeutics’ strategic execution and promising pipeline. The company is making significant progress with its lead program, pevifoscorvir sodium, which is currently in the Phase 2 B-SUPREME trial for chronic hepatitis B virus infection. The trial is actively enrolling patients, and interim data is expected in 2026, with topline results anticipated in 2027. This program has shown durable viral suppression and significant reductions in various hepatitis B antigens, which supports its potential as a monotherapy for chronic suppression.
Additionally, Aligos is exploring opportunities for its metabolic dysfunction-associated steatohepatitis program, ALG-055009, which could further enhance its pipeline. The company’s strategic positioning is bolstered by these developments, and the potential for pevifoscorvir sodium to replace existing treatments and act as a platform asset for next-generation HBV cures is particularly compelling. Trucchio estimates that the drug could generate peak annual revenues exceeding $1.8 billion, which underpins the reiterated Buy rating and a price target of $50 per share.